News Sentiment

AMRX sentiment intelligence

Amneal Pharmaceuticals, Inc. Class A Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 16.21 Week of 19 Jun 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 63

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+0.1% over one week, +30.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally

Market Reaction

Balanced read

58/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 30.5% over four weeks
Fair value 97.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 34
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 63
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 18
Market source 13
Sahm 7
simplywall.st 5
Investing.com 2
Seeking Alpha 2
Investing.com Nigeria 1
TradingView 1

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 15
Deals and strategy 5
Regulatory and legal 4
Guidance 3
Balance sheet 1
Macro sensitivity 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
Sahm Direct company coverage

Amneal Pharmaceuticals (AMRX) Profit Rebound Challenges Concerns Over Earnings Quality

Amneal Pharmaceuticals (AMRX) reported a profit rebound in FY 2025, with net income swinging to US$72.1 million, but the presence of a US$58.0 million one-off loss raises concerns about earnings quality. While a DCF fair value suggests the stock is undervalued, its high P/E ratio

Tone
Neutral 50/100
Event
Earnings
Published
09 May 2026 10:39
Source
Sahm
Stock Titan Direct company coverage

Amneal (NYSE: AMRX) director exercises 34,819 RSUs and receives new grant

Amneal Pharmaceuticals director J. Kevin Buchi exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common shares at no cost, increasing his direct holdings to 75,077 shares. He also received a new grant of 19,824 RSUs on May 6, 2026. This a

Tone
Neutral 50/100
Event
Market update
Published
09 May 2026 10:09
Source
Stock Titan
The Manila Times Direct company coverage

Amneal Reports First Quarter 2026 Financial Results

Amneal Pharmaceuticals reported a strong start to 2026, with first-quarter net revenue of $723 million, GAAP net income of $62 million, and adjusted EBITDA of $202 million. The company affirmed its previously announced increased full-year 2026 guidance, citing strong performance

Tone
Positive 72/100
Event
Earnings
Published
09 May 2026 00:10
Source
The Manila Times
Stock Titan Direct company coverage

[Form 4] Amneal Pharmaceuticals, Inc. Insider Trading Activity

Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into Class A Common Stock at $0.00 per share, bringing his direct ownership to 1,643,963 shares. Additionally, on M

Tone
Positive 61/100
Event
Deals and strategy
Published
08 May 2026 20:45
Source
Stock Titan
Stock Titan Direct company coverage

Director boosts stake with 34,819 shares in Amneal (NYSE: AMRX)

Amneal Pharmaceuticals director Ted C. Nark increased his equity stake by exercising 34,819 restricted stock units into Class A Common Stock shares on May 7, 2026. This transaction, part of a stock-based compensation, brought his direct holdings to 325,848 shares. Additionally, N

Tone
Positive 69/100
Event
Deals and strategy
Published
08 May 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Amneal (AMRX) director exercises RSUs, now holds 260,252 shares

Amneal Pharmaceuticals director John Kiely exercised 34,819 restricted stock units (RSUs) on May 7, 2026, receiving an equal number of Class A Common Stock shares at $0.00 per share. He also received a new RSU grant of 19,824 units on May 6, 2026. Following these transactions, Ki

Tone
Neutral 50/100
Event
Market update
Published
08 May 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Amneal (NYSE: AMRX) director exercises 48,747 RSUs and receives 30,837-unit grant

Amneal Pharmaceuticals director Paul M. Meister recently exercised 48,747 Restricted Stock Units, converting them into Class A shares, increasing his direct holdings to 832,800 shares. Additionally, he was granted a new 30,837 Restricted Stock Unit award. These transactions, deta

Tone
Neutral 50/100
Event
Market update
Published
08 May 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Amneal (NYSE: AMRX) director converts RSUs to shares and gets new grant

Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake by exercising 34,819 restricted stock units (RSUs) into Class A Common Stock. He also received a new grant of 19,824 restricted stock units, further boosting his potential share ownership in the company. Foll

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 May 2026 20:38
Source
Stock Titan
Stock Titan Direct company coverage

Amneal Pharmaceuticals (NASDAQ: AMRX) posts Q1 profit surge and inks $375M Kashiv acquisition

Amneal Pharmaceuticals reported a significant surge in Q1 2026 profit, with net income more than tripling to $78.0 million and diluted EPS at $0.19, driven by higher gross margins and strong Specialty segment performance. The company also announced a definitive agreement to acqui

Tone
Positive 62/100
Event
Deals and strategy
Published
08 May 2026 10:39
Source
Stock Titan